Concert Pharmaceuticals Inc

+0.46 (+7.50%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)239.40M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.17 Million
Adjusted EPS-$0.59
See more estimates
10-Day MA$5.85
50-Day MA$4.92
200-Day MA$3.74
See more pivots

Concert Pharmaceuticals Inc Stock, NASDAQ:CNCE

65 Hayden Avenue, Suite 3000N, Lexington, Massachusetts 02421
Phone: +1.781.860.0045
Number of Employees: 64


Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.